3/5/2014 9:34:02 AM
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today plans to present findings from research studies of its E-Selectin antagonist (GMI-1271) with three posters at the American Association for Cancer Research (AACR) Annual Meeting 2014. The posters will focus on the novel glycomimetic drug candidate’s potential as a treatment beyond hematological cancers to solid tumors (i.e., for breast cancer metastasis) as well as for its use in improving chemotherapy treatment. The AACR Annual Meeting 2014 will be held April 5-9 at the San Diego Convention Center.
Help employers find you! Check out all the jobs and post your resume.
comments powered by